June 26, 2022

Volume XII, Number 177

Advertisement
Advertisement

June 24, 2022

Subscribe to Latest Legal News and Analysis

June 23, 2022

Subscribe to Latest Legal News and Analysis

Supreme Court Issues Long-Awaited Decision in Christopher v. SmithKline Beecham Corp.

The U.S. Supreme Court has issued a long-awaited decision in Christopher v. SmithKline Beecham Corp., holding in a 5-4 decision that pharmaceutical sales employees are exempt outside salespeople. The decision may be read here. The case is significant for several reasons.

The central issue in Christopher was whether the pharmaceutical sales representatives were actually involved in "sales." The U.S. Department of Labor in "friend of the court" briefs has taken the position in recent years that an employee is making a sale only where the employee is involved in the transfer of title to customers. Pharmaceutical reps are "only" obtaining informal commitments from doctors to prescribe certain drugs.  The Court rejected the DOL's interpretation, finding it was not supported by the statute.

The decision also is significant in that it reminds employers that not every administrative decision will be supported by the courts. In a period where the National Labor Relations Board is scrutinizing social media policies, and the Equal Employment Opportunity Commission is attacking background checking procedures, it is worth remembering that these interpretations of federal agencies may not stand up to judicial scrutiny in the medium term. No employer wants to be the "test case," but employers should discuss this aspect of administrative guidance with counsel when formulating their compliance strategies.  (Another example reported on last week is here.) 

Along the same lines, this decision confirms that courts will not necessarily defer to agency changes in established enforcement positions without the agency going through the required rule-making process.  Indeed, the majority held that the DOL's new interpretation offered for the first time in an amicus brief created an "unfair surprise" for the pharmaceutical industry, which had not been given notice or a chance to comment on the new interpretation through the rule-making process.

Finally, both the closeness of the decision and the fact that the dispute arose from the DOL taking a more aggressive position with the change in administration in 2009 emphasize the significance of the upcoming Presidential election for how these issues are likely to play out in the next few years.

Any business relying on the outside sales exemption (or considering doing so) should review this decision with counsel to ensure compliance.

© 2022 BARNES & THORNBURG LLPNational Law Review, Volume II, Number 172
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Barnes & Thornburg’s Labor and Employment Law Department is one of the fastest-growing labor groups in the nation. Two qualities set us apart: Our passion for what we do, and the pride we take in helping clients achieve their business goals. To succeed in the competitive global marketplace, our clients must not only meet but exceed their customers’ expectations. We share this objective, offering superior service, innovative ideas and an understanding of the challenges our clients face.

We love what we do in large part because we love what our clients do – not just...

317-231-7513
Advertisement
Advertisement
Advertisement